AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Memphasys

0.005

+0.000

Volume:6.43M

Turnover:32.14K

Market Cap:9.92M

PE:-1.73

High:0.005

Open:0.005

Low:0.005

Close:0.005

Loading ...

Overview Company News Filings

BRIEF-Memphasys Seeks Trading Halt

Memphasys Ltd - Seeks Trading Halt Pending Announcement on Proposed Capital Raising

THOMSON REUTERS

Memphasys Ltd-Proposed Issue of Securities - Mem

THOMSON REUTERS

Memphasys Ltd-Roxsta Offers Effective Oxidative Stress Measurem't 4 Cattle

THOMSON REUTERS

Memphasys achieves key milestone with clinical validation of Felix fertility device

BUZZ-Australia's Memphasys soars on upbeat trial results for sperm selection device

Monday’s HotCopper Trends: Opthea strife, Errawarra jumps on acquisitions, Memphasys best-in-class trial results | March 21, 2025

The Market Herald

Memphasys tech: Trial results prove it lifts the guys’ game in IVF

The Market Herald

BRIEF-Memphasys Seeks Trading Halt

Here's Why Memphasys (ASX:MEM) Can Afford Some Debt

Simply Wall St.

Memphasys Completes Felix System Clinical Trial, Shares Rise Past 14%

MT Newswires Live

Memphasys Says Publication of Study Demonstrates Oxidative Stress Profiling System Potential

MT Newswires Live

Publication highlights strengths of Memphasys’ antioxidant profiling system

The Market Herald

Memphasys to Start Utilization Testing of Reproductive Biotechnology Product in China

MT Newswires Live

BRIEF-Memphasys Signs Letter Of Intent With Heranova

ASX Small-Cap Stocks to Watch

MT Newswires Live

Memphasys - Signs Letter of Intent With Heranova for Felixtm System Distribution in Greater China

THOMSON REUTERS

Sperm tech player Memphasys ships unit to Dubai – but can the stock attract liquidity?

The Market Herald

BRIEF-Memphasys Announces Order For Felix System To Evaluate Suitability In UAE

Memphasys Ltd - Order for Felix System to Evaluate Suitability in UAE

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MEM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MEM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEM.AU\",,,,,undefined,":{"symbol":"MEM.AU","market":"AU","secType":"STK","nameCN":"Memphasys","latestPrice":0.005,"timestamp":1745302320000,"preClose":0.005,"halted":0,"volume":6427679,"delay":0,"nameEN":"Memphasys","floatShares":1020316318,"shares":1983598100,"eps":-0.002883,"marketStatus":"Closed","change":0,"latestTime":"04-22 16:12:00 AEST","open":0.005,"high":0.005,"low":0.005,"amount":32138,"amplitude":0,"askPrice":0.006,"askSize":6642033,"bidPrice":0.005,"bidSize":13821664,"shortable":3,"etf":0,"ttmEps":-0.002883,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.005,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":1.195781,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEM.AU\",,,,,undefined,":{"symbol":"MEM.AU","floatShares":1020316318,"roa":"-18.49%","roe":"-80.47%","lyrEps":-0.003212,"volumeRatio":1.195781,"shares":1983598100,"dividePrice":0,"high":0.005,"amplitude":0,"preClose":0.005,"low":0.005,"week52Low":0.004,"pbRate":"1.63","psRate":"9.23","week52High":0.012,"institutionHeld":0,"latestPrice":0.005,"committee":0.350847,"eps":-0.002883,"divideRate":0,"volume":6427679,"delay":0,"ttmEps":-0.002883,"open":0.005,"prevYearClose":0.008,"prevWeekClose":0.005,"prevMonthClose":0.009,"prevQuarterClose":0.009,"fiveDayClose":0.007,"twentyDayClose":0.007,"sixtyDayClose":0.007},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526032734","title":"BRIEF-Memphasys Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2526032734","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526032734?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:34","pubTimestamp":1744248867,"startTime":"0","endTime":"0","summary":"BRIEF-Memphasys Seeks Trading HaltApril 10 (Reuters) - Memphasys Ltd MEM.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON PROPOSED CAPITAL RAISINGFurther company coverage: MEM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN1B4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEM.AU","BK7048"],"gpt_icon":0},{"id":"2526220393","title":"Memphasys Ltd -  Seeks Trading Halt Pending Announcement on Proposed Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2526220393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526220393?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:33","pubTimestamp":1744248836,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN1B4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEM.AU","BK7048"],"gpt_icon":0},{"id":"2526519342","title":"Memphasys Ltd-Proposed Issue of Securities - Mem","url":"https://stock-news.laohu8.com/highlight/detail?id=2526519342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526519342?lang=en_us&edition=fundamental","pubTime":"2025-04-10 06:20","pubTimestamp":1744237214,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nTUEBVQV5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEM.AU","BK7048"],"gpt_icon":0},{"id":"2524440297","title":"Memphasys Ltd-Roxsta Offers Effective Oxidative Stress Measurem't 4 Cattle","url":"https://stock-news.laohu8.com/highlight/detail?id=2524440297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524440297?lang=en_us&edition=fundamental","pubTime":"2025-04-03 06:53","pubTimestamp":1743634439,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nTUE9LCB5N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","MEM.AU"],"gpt_icon":0},{"id":"2521568759","title":"Memphasys achieves key milestone with clinical validation of Felix fertility device","url":"https://stock-news.laohu8.com/highlight/detail?id=2521568759","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521568759?lang=en_us&edition=fundamental","pubTime":"2025-03-24 11:49","pubTimestamp":1742788164,"startTime":"0","endTime":"0","summary":"Memphasys  has published positive data from a pivotal clinical trial of its Felix electrophoresis-based sperm separation device for use in assisted reproduction.The trial validated the ability of the Felix device to meet and exceed industry benchmarks and found it to be non-inferior to the “swim-up” technique but statistically superior to DGC , the world’s most commonly used sperm preparation method.The company conducted the trial, which confirmed the device to have best-in-class performance in sperm selection for human fertility treatments, in partnership with Perth-based clinic Monash IVF Australia.Felix also demonstrated a positive primary endpoint of improved embryo utilisation compared with swim-up and DGC.Specifically, the number of embryos utilised divided by the total number of embryos created, a benchmark of assisted reproduction cycle success.Memphasys chief executive officer David Ali said the Felix trial was the most rigorous study ever conducted for a sperm separation devi","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/Memphasys-ASX-MEM-Felix-Clinical-Trial-Confirms-Best-in-Class-Performance.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/Memphasys-ASX-MEM-Felix-Clinical-Trial-Confirms-Best-in-Class-Performance.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/memphasys-clinical-validation-felix-fertility-device/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["MEM","BK7048","MEM.AU"],"gpt_icon":0},{"id":"2521174730","title":"BUZZ-Australia's Memphasys soars on upbeat trial results for sperm selection device","url":"https://stock-news.laohu8.com/highlight/detail?id=2521174730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521174730?lang=en_us&edition=fundamental","pubTime":"2025-03-24 11:03","pubTimestamp":1742785390,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Memphasys soars on upbeat trial results for sperm selection device** Memphasys MEM.AX soars as much as 57.1% to A$0.011, set for biggest intraday gain since August 18, 2022** Stock hits highest since January 6** Medical devices maker reports positive clinical trial results for its Felix sperm selection system** Says results exceed industry benchmarks in sperm selection for assisted reproductive technology** Stock logs busiest trading day since October 2018, with ~50.3 mln shares traded vs 30-day avg of ~1.8 mln** MEM last up ~43%, extends YTD gains to 25%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL3N3Q706V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","MEM.AU"],"gpt_icon":0},{"id":"2521734542","title":"Monday’s HotCopper Trends: Opthea strife, Errawarra jumps on acquisitions, Memphasys best-in-class trial results | March 21, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521734542","media":"The Market Herald","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521734542?lang=en_us&edition=fundamental","pubTime":"2025-03-24 10:13","pubTimestamp":1742782380,"startTime":"0","endTime":"0","summary":"The ASX has been trading flat at around 7,928 points.Discretionary has been the best performing sector today, up 1%, followed by Financials, up 0.66%, and Utilities, up 0.5%.Staples has been the worst performing, down 1%, followed by Materials, down 0.9%, and Industrials, down 0.8%.Opthea  has been the most watched on HotCopper forums today and is in a trading halt. Its COAST Phase 3 trial failed to meet primary endpoint of mean change in best corrected visual acuity from baseline to Week 52. The company is now considering the overall impact of the negative trial result heading into the year.Also trending: Errawarra Resources , which has entered binding agreements to acquire 70% of the historical Elizabeth Hill Silver Project, 70% of the silver rights to the Pinderi Hills Project tenement package, and 70% of the ownership of three tenements surrounding the silver project.Rounding out the most discussed has been Memphasys , which unveiled the successful unblinding and data analysis of i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/mondays-hotcopper-trends-opthea-strife-errawarra-jumps-on-acquisitions-memphasys-best-in-class-trial-results-march-21-2025-2025-03-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7048","MEM.AU","OPT","BK7067","BK7095","ERW.AU","MEM","OPT.AU","BK7508"],"gpt_icon":0},{"id":"2521102733","title":"Memphasys tech: Trial results prove it lifts the guys’ game in IVF","url":"https://stock-news.laohu8.com/highlight/detail?id=2521102733","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521102733?lang=en_us&edition=fundamental","pubTime":"2025-03-24 07:07","pubTimestamp":1742771220,"startTime":"0","endTime":"0","summary":"Reproductive technology developed by Memphasys  is proving to be a gamechanger in addressing the men’s side of infertility – which is now understood to cause at least half of all conception issues.The company’s Felix System has successfully completed its Phase III clinical trial, proving it works faster than traditional methods, without adverse effects, and with scientists preferring it over the most widely used traditional IVF technologies.Memphasys reached its primary endpoint comparing its Embryo Utilisation Rateagainst existing Density Gradient Centrifugation  and Swim-Up IVF techniques.The trial has proven Felix is as good as the Swim-Up technique and “superior” to the world’s most used DGC method. And, Felix has other benefits in relation to both existing methods, which I’ll run through shortly.Memphasys partnered with Monash IVF Group , another Australian reproductive and fertility services company, for the trials.It’s in this male reproduction side where Memphasys is positioned","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/memphasys-tech-trial-results-prove-it-lifts-the-guys-game-in-ivf-2025-03-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["ART.AU","BK7508","BK7113","BK7048","MVF.AU","MEM.AU","UAE","MEM","BK7002"],"gpt_icon":0},{"id":"2520190840","title":"BRIEF-Memphasys Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2520190840","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520190840?lang=en_us&edition=fundamental","pubTime":"2025-03-20 06:18","pubTimestamp":1742422703,"startTime":"0","endTime":"0","summary":"BRIEF-Memphasys Seeks Trading HaltMarch 20 (Reuters) - Memphasys Ltd MEM.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON  FELIX SYSTEM CLINICAL TRIAL RESULTSFurther company coverage: MEM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q213D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEM.AU","BK7048"],"gpt_icon":0},{"id":"2516572818","title":"Here's Why Memphasys (ASX:MEM) Can Afford Some Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2516572818","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516572818?lang=en_us&edition=fundamental","pubTime":"2025-03-03 07:33","pubTimestamp":1740958437,"startTime":"0","endTime":"0","summary":"Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-mem/memphasys-shares/news/heres-why-memphasys-asxmem-can-afford-some-debt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MEM","EBIT","BK7048","MEM.AU"],"gpt_icon":0},{"id":"2510878158","title":"Memphasys Completes Felix System Clinical Trial, Shares Rise Past 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510878158","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510878158?lang=en_us&edition=fundamental","pubTime":"2025-02-11 15:00","pubTimestamp":1739257236,"startTime":"0","endTime":"0","summary":"Memphasys  completed a clinical trial of its advanced sperm selection technology, Felix System, for assisted reproductive technology procedures, according to a Tuesday Australian bourse filing.It achieved the last patient visit in the trial, with all required patient visits, including pregnancy outcomes completed, the filing said.Data lock is anticipated in around two weeks, following a final data clean-up, management, and source verification phase.It will use the trial data as part of its ongoing CE Mark submission to advanced commercialization activities in Europe. Regulatory approvals in Australia and India are expected to follow soon after.The firm's shares rose past 14% on market close on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7048","XAO.AU","XJO.AU","XKO.AU","MEM","MEM.AU"],"gpt_icon":0},{"id":"2503984990","title":"Memphasys Says Publication of Study Demonstrates Oxidative Stress Profiling System Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2503984990","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503984990?lang=en_us&edition=fundamental","pubTime":"2025-01-16 10:44","pubTimestamp":1736995457,"startTime":"0","endTime":"0","summary":"Memphasys   said the publication of a study in the \"Antioxidants\" journal reinforces the commercial potential as well as the scientific credibility of its RoXsta platform to identify oxidative stress in human and animal samples, according to a Thursday Australian bourse filing.RoXsta is a proprietary antioxidant diagnostic platform for identifying oxidative stress-related deficiencies, and the study supports its ability to diagnose oxidative stress through analysis of biological fluids, the filing added.The RoXsta system has potential for male infertility treatments as well as disease management in conditions such as neurodegenerative diseases, cardiovascular disorders, and cancer, the filing said.It is also exploring its potential for the optimization of livestock productivity by mitigating oxidative stress.Oxidative stress is linked to infertility, cardiovascular disease, neurodegenerative disorders, cancer, and other conditions, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7048","MEM","MEM.AU"],"gpt_icon":0},{"id":"2503604638","title":"Publication highlights strengths of Memphasys’ antioxidant profiling system","url":"https://stock-news.laohu8.com/highlight/detail?id=2503604638","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503604638?lang=en_us&edition=fundamental","pubTime":"2025-01-16 07:28","pubTimestamp":1736983680,"startTime":"0","endTime":"0","summary":"Memphasys Ltd  has seen a boost to its proprietary antioxidant profiling system RoXsta through the publication of a recent manuscript that emphasises its commercial potential and scientific credibility.The publication, ‘A Comparative Analysis of the Antioxidant Profiles Generated by the RoXsta System for Diverse Biological Fluids,’ appeared in the prestigious journal Antioxidants and was co-authored by Laureate Professor John Aitken, Memphasys’ scientific director, and a team of researchers from the University of Newcastle.Managing director and CEO of Memphasys David Ali said the manuscript was a testament to RoXsta’s transformative capabilities.“Its diagnostic power not only reinforces Memphasys’ leadership in reproductive health but also positions us for broader market opportunities in livestock and clinical applications.Join the discussion:See what HotCopperusers are saying aboutMemphasys Ltd and be part of the conversations that move the markets.The material provided in this articl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/publication-highlights-strengths-of-memphasys-antioxidant-profiling-system-2025-01-16/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7048","MEM","MEM.AU"],"gpt_icon":0},{"id":"2501426779","title":"Memphasys to Start Utilization Testing of Reproductive Biotechnology Product in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2501426779","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501426779?lang=en_us&edition=fundamental","pubTime":"2025-01-06 09:07","pubTimestamp":1736125631,"startTime":"0","endTime":"0","summary":"Memphasys  will start in vitro utilization testing of its Felix System in China as part of an agreement with Hong Kong-based biotech company Heranova Lifesciences HK, according to a Monday filing with the Australian bourse.Heranova will conduct testing at Sichuan Jinxin Xinan Women & Children Hospital in Chengdu to assess the usability of the system in routine and challenging in vitro fertilization cases using 50 patient cases, with the company supplying 50 Felix cartridges and one console, the filing said.The testing will assess the biological performance and health economic benefits of the system, according to the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEM.AU","BK7048","MEM"],"gpt_icon":0},{"id":"2490142843","title":"BRIEF-Memphasys Signs Letter Of Intent With Heranova","url":"https://stock-news.laohu8.com/highlight/detail?id=2490142843","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490142843?lang=en_us&edition=fundamental","pubTime":"2024-12-12 09:03","pubTimestamp":1733965404,"startTime":"0","endTime":"0","summary":"Dec 12 (Reuters) - Memphasys Ltd   :   * SIGNS LETTER OF INTENT WITH HERANOVA FOR FELIXTM SYSTEM DISTRIBUTION IN GREATER CHINA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","MEM.AU"],"gpt_icon":0},{"id":"2490181219","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2490181219","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490181219?lang=en_us&edition=fundamental","pubTime":"2024-12-12 07:38","pubTimestamp":1733960321,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.Memphasys (ASX:MEM)The biotechnology company signed a letter of intent with Heranova ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7016","MEM.AU","BK7095","VEN.AU","GLL.AU","PAT.AU","SRR.AU","BK7048","MEM","BK7142","BK7104","IXU.AU"],"gpt_icon":0},{"id":"2490797818","title":"Memphasys - Signs Letter of Intent With Heranova for Felixtm System Distribution in Greater China","url":"https://stock-news.laohu8.com/highlight/detail?id=2490797818","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490797818?lang=en_us&edition=fundamental","pubTime":"2024-12-12 05:17","pubTimestamp":1733951868,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NC1FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","MEM.AU"],"gpt_icon":0},{"id":"2489705141","title":"Sperm tech player Memphasys ships unit to Dubai – but can the stock attract liquidity?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489705141","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489705141?lang=en_us&edition=fundamental","pubTime":"2024-12-05 10:42","pubTimestamp":1733366520,"startTime":"0","endTime":"0","summary":"Biotech nanocap Memphasys  has sent a demo unit of its Felix sperm separator system to a hospital in Dubai, United Arab Emirates.In short, to make artificial insemination work, you need to separate the actual sperm from semen, which is otherwise just another version of something the human body is pretty good at making: Mucus. . The Felix device uses the same process used to separate DNA and protein molecules from other mediums – electrophoresis.It works like this: Individual sperms happen to carry a negative charge due to their chemistry – going into why is incredibly boring – and so by placing the semen in a conductive salted gel, adding some membranes, and playing around with electricity thereafter, you eventually end up with isolated sperm.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decision","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/sperm-tech-player-memphasys-ships-unit-to-dubai-but-can-the-stock-attract-liquidity-2024-12-05/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7048","MEM","MEM.AU"],"gpt_icon":0},{"id":"2489768171","title":"BRIEF-Memphasys Announces Order For Felix System To Evaluate Suitability In UAE","url":"https://stock-news.laohu8.com/highlight/detail?id=2489768171","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489768171?lang=en_us&edition=fundamental","pubTime":"2024-12-05 09:19","pubTimestamp":1733361581,"startTime":"0","endTime":"0","summary":"Dec 5 (Reuters) - Memphasys Ltd   :   * ORDER FOR FELIX SYSTEM TO EVALUATE SUITABILITY IN UAEFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","MEM.AU"],"gpt_icon":0},{"id":"2489509129","title":"Memphasys Ltd - Order for Felix System to Evaluate Suitability in UAE","url":"https://stock-news.laohu8.com/highlight/detail?id=2489509129","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489509129?lang=en_us&edition=fundamental","pubTime":"2024-12-05 06:47","pubTimestamp":1733352476,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N5209:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","MEM.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEM.AU\",params:#limit:5,,,undefined,":[{"date":"2022-09-01","symbol":"MEM.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1661990400000,"name":null,"time":"","dateTimestamp":1661954400000,"actualEps":null},{"market":"AU","date":"2022-08-23","symbol":"MEM.AU","defaultRemindTime":1661212800000,"type":"split","dateTimestamp":1661176800000,"forFactor":954054,"toFactor":1000000,"ratio":0.954054}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEM.AU\",market:\"AU\",,,undefined,":[]}}